Cataract Surgery

Pain-preventing NSAID welcomed by patients and cliniciansA new 0.075% formulation of bromfenac ophthalmic solution (BromSite, Sun Pharma) could provide relief from pain and inflammation associated with cataract surgery.
Dr. Mali's top 5 predictions in ophthalmology for 2017The great thing about making predictions is that it is basically a win-win proposition: if you are correct in your predictions, you are celebrated for being a sage. If you are incorrect, you have the opportunity to learn from them and make better predictions for the next year. Wishing everyone a Happy New Year and a successful 2017!
16 most popular stories of 2016
16 most popular stories of 2016Here is your roundup of what made top news in 2016!
LENSAR files for bankruptcy with PDL BioPharma support
LENSAR files for bankruptcy with PDL BioPharma supportLENSAR Inc. announced its filing of a Chapter 11 bankruptcy petition on Dec. 19 to reduce its debt, strengthen its balance sheet, and strengthen its platform for future growth, according to a press release from the company.
NSAID after Dropless approach shown to lower CMEThere was clinically significant less CME in patients who received trans-zonular triamcinolone acetonide, moxifloxacin hydrochloride, and vancomycin—known as the Dropless approach—in addition to an NSAID after cataract surgery.
Know your options when expanding a pupilHumans are creatures of habit, even ophthalmologists. Having learned to use one device for pupil expansion, it is easy to forget that there are alternative devices.
Year in review: Cataract surgeryLooking back over the past year and into the near future, Eric D. Donnenfeld, MD, Robert H. Osher, MD, and Mark Packer, MD, spoke to Ophthalmology Times about developments in diagnostic products and other tools used in cataract surgery. In addition, they discussed combination microinvasive glaucoma surgery (MIGS) and office-based surgery as new trends.
Approval of a new class of implants tops cataract surgery newsCataract surgeons in the United States have long been envious of the IOL options available to their international colleagues. Finally, in 2016, American ophthalmologists gained access to some novel IOLs such as the Tecnis Symfony Extended Range of Vision IOL and the Tecnis Symfony Toric IOL (Abbott) that were approved by the FDA. According to leading cataract surgeons who spoke to Ophthalmology Times, these simultaneous approvals rank as the biggest cataract surgery news story of the year.
Cataract surgery 2016: News from the pharmaceutical frontA review of some of the most significant advances in medications for cataract surgery during the past year revealed a mix of the expected with a few surprises.
Capsulotomy creation: Benefits with low risksFindings from an updated analysis of outcomes at a single center reaffirm the safety of femtosecond laser capsulotomy by showing it is associated with a low rate of anterior capsule tears.